Tag:
Corgentech
Latest Headlines
Latest Headlines
Data backs Corgentech pain drug
Shares of Corgentech surged on news that a mid-stage trial produced positive data for 4975, the company's experimental pain therapy. The data demonstrated that patients recovering from knee replacement surgery experienced significantly lower pain scores while taking 4975. Subjects in the 50-patient study were given a combination of either morphine and 4975 or morphine and a placebo.
"4975 has demonstrated its ability to provide relief of acute and chronic pain to patients …
C&L: Phase III Medical taps Robin Smith as CEO
Phase III Medical has named Robin L. Smith , MD, MBA as chairman of the board and CEO.
Alpharma has named Dean J. Mitchell president and CEO, effective July 1. Mitchell will succeed Ingrid Wiik , who previously announced she planned to retire as CEO once a successor was named.
Affibody AB has appointed …
C&L: MultiCell Technologies names Chang CEO
MultiCell Technologies has appointed Stephen M. Chang , Ph.D. as its new CEO in addition to his current role as president.
PAREXEL International has named Douglas A. Batt senior vice president and general counsel.
MGI PHARMA announced that Gerard T. Kennealey , M.D. has joined the management team in the …
Corgentech drug fails to outperform placebo
A small Phase II trial of Corgentech's 4975 for hernia pain failed to demonstrate a difference between the drug and a placebo. Patients either received a mix of paracetamol and ibuprofen along with either the experimental drug or a placebo. Researchers blamed the mix of pain drugs for all patients as a reason for the flat response rate.
"We believe that concomitant administration of pain killing drugs may have confounded the results of this trial since the results are inconsistent …
Corgentech gets positive Phase II data
Corgentech has reported positive clinical data from a Phase II clinical trial showing that the non-opioid pain management drug ALGRX 4975 demonstrated statistically significant pain relief over placebo in patients with tendonitis of the elbow, or "tennis elbow."
- read this release for more
ALSO NOTED: Researchers announce cancer cases in AIDS research; FDA meets on Cubicin; and much more...
> Schering-Plough announced that five patients taking its experimental AIDS therapy vicriviroc contracted cancer but added that no causal relationship had been established. Report
> Shares of Cubist Pharmaceuticals dropped on Friday as investors braced for an FDA advisory meeting today on whether to expand use of Cubicin antibiotic. …
ALSO NOTED: Warner Chilcott contraceptive approved; Inspire inks deal with Boehringer;and much more...
> The FDA approved Warner Chilcott's 24-day contraceptive Loestrin(R) 24 Fe. This is the first 24-day contraceptive to hit the U.S. market. Warner Chilcott focuses on dermatology and women's health. "This FDA approval is a significant step forward for Warner Chilcott as we continue to sharpen our therapeutic focus on women's health and expand our product portfolio in this area," said Roger Boissonneault, CEO. …
ALSO NOTED: FDA panel recommends Zostavax; Serono pleads guilty; Wistar Institute sells royalties;and much more...
> An expert FDA panel has recommended Merck's Zostavax for people 60 or over. The vaccine is designed to prevent shingles. Report
> Switzerland's Serono has pled guilty to criminal charges that it paid kickbacks to doctors in order to boost falling sales of its drugs and formally agreed to pay $704 million to settle criminal fines and civil claims. Prosecutors …
ALSO NOTED: EMA grants Nuvelo orphan drug designation; AlgoRx, Corgentech's pain drug show promise; and much more...
> Nuvelo has received an orphan drug designation from the European Medicines Agency for alfimeprase, a product Nuvelo hopes will treat peripheral arterial occlusion (PAO). The drug has already received orphan indication status from the FDA. Release
> AlgoRx and Corgentech have promising data from their phase III local anesthetic ALGRX 3268, a powder injection for pain. …
DEALS: Corgentech, AlgoRx to merge pipelines
Corgentech, AlgoRx to merge pipelines
